Business
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 SAN MATEO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will present a poster a
About this update from Sagimet Biosciences Inc. - Series A
[{"type":"image","alt":"Sagimet Biosciences Inc.","displaySize":"","headline":null,"caption":"Sagimet Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C32fg84LArApitrpx4c7VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NA--/https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25","width":300,"height":110},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/C32fg84LArApitrpx4c7VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NA--/https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25","width":300,"height":110}},"lazy":false},{"type":"text","content":"Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne ","length":90,"tagName":"p"},{"type":"text","content":"Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026","length":130,"tagName":"p"},{"type":"text","content":"SAN MATEO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will present a poster at the 83rd Society for Investigative Dermatology Annual Meeting (SID 2026) on May 15, 2026 showing in vitro data that supports the potential use of FASN inhibitors in acne.","length":451,"tagName":"p"},{"type":"text","content":"“Excess sebum production is one of the key drivers of acne,” said Andreas Grauer, MD, Sagimet’s Chief Medical Officer. “At SID 2026, we will present data from our preclinical studies which showed that FASN inhibitors reduced sebum-related lipids in human sebocytes. These data, added to the successful Phase 3 clinical trial of denifanstat in acne in China, demonstrate that FASN inhibition offers a potential mechanism of action to treat acne, and support our Phase 3 registrational clinical trial in acne planned to start in the second half of 2026.”","length":552,"tagName":"p"},{"type":"text","content":"Society for Investigative Dermatology Poster Presentation Details:","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Poster Ti...